ABBV On Other Exchanges
New York
EN Paris
Sao Paulo
text size: T | T
Back to Snapshot
Company Description

Contact Info

1 North Waukegan Road

North Chicago, IL 60064

United States

Phone: 847-932-7900


products include KALETRA and Norvir for the treatment of HIV infection and Synagis for the prevention of respiratory syncytial virus (RSV) infection in high risk infants. KALETRA: KALETRA (lopinavir/ritonavir), which is also marketed as Aluvia in emerging markets, is a prescription anti-HIV-1 medicine that contains two protease inhibitors, such as lopinavir and ritonavir. Kaletra is used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1. Norvir: Norvir (ritonavir) is a protease inhibitor that is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. Synagis: Synagis (palivizumab) is a product marketed by the company outside of the United States that protects at-risk infants from severe respiratory disease caused by RSV. Metabolics/Hormones Products Metabolic and hormone products target various conditions, including testosterone deficiency, exocrine pancreatic insufficiency and hypothyroidism. These products comprise: AndroGel: AndroGel (testosterone gel) is a testosterone replacement therapy for males diagnosed with symptomatic low testosterone that is available in two strengths, 1 percent and 1.62 percent. Creon: Creon (pancrelipase) is a pancreatic enzyme therapy for exocrine pancreatic insufficiency, a condition that occurs in patients with cystic fibrosis, chronic pancreatitis, and various other conditions. Synthroid: Synthroid (levothyroxine sodium tablets, USP) is used in the treatment of hypothyroidism. The company has the rights to sell AndroGel, Creon and Synthroid in the United States. Endocrinology Products Lupron (levprolide acetate), which is also marketed as Lucrin and Lupron Depot, is a product for the palliative treatment of advanced prostate cancer, treatment of endometriosis and central precocious puberty, and for the preoperative treatment of patients with anemia caused by uterine fibroids. Lupron is approved for daily subcutaneous injection and one-month, three-month, four-month and six-month intramuscular injection. Other Products The company’s other products include the following: Duopa and Duodopa (carbidopa and levodopa): The company’s levodopa-carbidopa intestinal gel for the treatment of advanced Parkinson's disease is marketed as Duopa in the United States and as Duodopa outside of the United States. Anesthesia Products: Sevoflurane (sold under the trademarks Ultane and Sevorane) is an anesthesia product that the company sells worldwide for human use. Dyslipidemia Products: The company’s dyslipidemia products (TriCor (fenofibrate), Trilipix (fenofibric acid), and Niaspan (niacin extended-release)) address the range of metabolic conditions characterized by high cholesterol and/or high triglycerides. Zemplar: Zemplar (paricalcitol) is a product sold worldwide for the treatment of secondary hyperparathyroidism associated with Stage 3, 4, and 5 chronic kidney disease. Marketing, Sales, and Distribution The company utilizes a combination of commercial resources, regional commercial resources and distributorships to market, sell, and distribute its products worldwide. The company directs its primary marketing efforts toward securing the prescription, or recommendation, of its brand of products by physicians, key opinion leaders, and other health care providers. Managed care providers (such as health maintenance organizations and pharmacy benefit managers), hospitals, and state and federal government agencies (such as the United States Department of Veterans Affairs and the United States Department of Defense) are also primary customers. The company also markets directly to consumers themselves, although in the United States all of the company's products must be sold pursuant to a prescription. Outside of the United States, the company focuses its marketing efforts on key opinion leaders, payors, physicians, and country regulatory bodies. The company also provides patient support programs closely related to its products. The company’s products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities,


The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. does not create or control the content.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

ABBV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ABBV.
View Industry Companies

Industry Analysis


Industry Average

Valuation ABBV Industry Range
Price/Earnings 19.5x
Price/Sales 4.4x
Price/Book 22.6x
Price/Cash Flow 19.2x
TEV/Sales 2.7x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ABBVIE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at